NCT07522008Recruiting
ICHARUS: Italian Cooperative HemoAdsorption Study for Relief of Uremic Symptoms
ICHARUS: Italian Cooperative HemoAdsorption Study for Relief of Uremic Symptoms. A Prospective Observational Cohort Study to Assess the Effectiveness and Safety of Hemoadsorption in Chronic Hemodialysis Patients With Refractory Uremic Symptoms: An Italian Real-World Registry.
Source: ClinicalTrials.gov · Last updated 21 Apr 2026
Brief summary (registry, in English)
Background: Many patients receiving maintenance hemodialysis continue to experience persistent uremic symptoms, such as pruritus, fatigue, sleep disorders, reduced physical performance, and impaired quality of life, despite optimized dialysis prescriptions. Conventional dialysis techniques mainly rely on diffusion and convection and may be insufficient to remove certain uremic toxins, particularly protein-bound and middle-molecule solutes. Purpose: The ICHARUS study (Italian Cooperative HemoAdsorption Study for Relief of Uremic Symptoms) is a prospective, observational, real-world registry designed to evaluate the clinical use of hemodialysis combined with hemoadsorption (HAHD) in patients with persistent uremic symptoms. Study design: ICHARUS is a multicenter registry enrolling adult patients on maintenance hemodialysis in whom hemoadsorption is prescribed according to routine clinical practice. Hemoadsorption is added to standard dialysis sessions without modifying the underlying dialysis modality or prescription. The study does not involve randomization or experimental interventions. Outcomes: The registry will collect data on patient-reported symptoms, quality of life, selected laboratory parameters, and safety outcomes at baseline and during follow-up at 1, 3, and 6 months. The aim is to describe symptom evolution, tolerability, and real-world treatment patterns associated with HAHD. Significance: By collecting standardized real-world data across multiple centers, the ICHARUS registry aims to improve understanding of the potential role of hemoadsorption in chronic hemodialysis, support harmonization of clinical practice, and generate hypotheses for future interventional studies.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 120 (estimated)
- First submitted
- 14 Mar 2026
- Start date
- Mar 2026
- Primary completion date
- Feb 2027
- Lead sponsor
- Azienda Ospedaliera Brotzu
- Diseases
- Chronic kidney disease
- NCT number
- NCT07522008
What you commit to
- Study type: Observational
- Planned participants: 120
- From Mar 2026 to the primary completion date, Feb 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Acute illness, active infection, or hospitalization within 4 weeks prior to enrollment.
- Planned kidney transplantation within the study follow-up period.
Other illness
- Life expectancy less than 6 months due to non-renal comorbid conditions.
Other
- Inability to complete patient-reported outcome questionnaires.
- Participation in another interventional clinical study that could interfere with study outcomes.
Who the study is looking for
- Adult patients (≥18 years) with end-stage kidney disease (CKD stage 5D) on maintenance hemodialysis.
- Stable hemodialysis treatment for at least 3 months prior to enrollment.
- Presence of at least one moderate-to-severe uremic symptom, as identified by the Dialysis Symptom Index at screening.
- Planned treatment with hemodialysis combined with hemoadsorption according to local clinical practice.
- Ability to provide written informed consent.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| S.C.D.U. Nefrologia, Dialisi e Trapianto ARNAS G.Brotzu, Cagliari Coordinator of this site? Confirm its status | Cagliari | Italy | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.